JP2020521798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521798A5 JP2020521798A5 JP2019566227A JP2019566227A JP2020521798A5 JP 2020521798 A5 JP2020521798 A5 JP 2020521798A5 JP 2019566227 A JP2019566227 A JP 2019566227A JP 2019566227 A JP2019566227 A JP 2019566227A JP 2020521798 A5 JP2020521798 A5 JP 2020521798A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- use according
- medicament
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003862 glucocorticoid Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000002411 adverse Effects 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 229940079593 drug Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 description 20
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173980.8 | 2017-06-01 | ||
| EP17173980.8A EP3409322A1 (en) | 2017-06-01 | 2017-06-01 | Treatment method |
| PCT/EP2018/063996 WO2018219901A1 (en) | 2017-06-01 | 2018-05-29 | Treatment method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521798A JP2020521798A (ja) | 2020-07-27 |
| JP2020521798A5 true JP2020521798A5 (enExample) | 2021-07-26 |
Family
ID=59030785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566227A Pending JP2020521798A (ja) | 2017-06-01 | 2018-05-29 | 治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200199230A1 (enExample) |
| EP (2) | EP3409322A1 (enExample) |
| JP (1) | JP2020521798A (enExample) |
| KR (1) | KR20200014345A (enExample) |
| CN (1) | CN110678228A (enExample) |
| AU (1) | AU2018276345B2 (enExample) |
| BR (1) | BR112019025062A2 (enExample) |
| CA (1) | CA3064668A1 (enExample) |
| IL (1) | IL270867A (enExample) |
| MX (1) | MX2019014291A (enExample) |
| TW (1) | TWI892958B (enExample) |
| WO (1) | WO2018219901A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022059998A1 (ko) * | 2020-09-15 | 2022-03-24 | 신지섭 | 면역세포증식활성화키트 및 상기 증식활성화키트를 이용한 면역세포배양방법 |
| EP4223778A4 (en) * | 2020-09-29 | 2024-11-06 | Innovent Biologics (Singapore) Pte. Ltd. | BISPECIFIC ANTIBODY TO CLAUDIN 18.2 AND CD3 AND ITS USE |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| ES2526343T3 (es) | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| PL1874821T3 (pl) * | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| JP2013505223A (ja) * | 2009-09-18 | 2013-02-14 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | ＥｐＣＡＭｘＣＤ３二重特異性抗体を投与するための投与計画 |
| CN103533943B (zh) * | 2010-11-10 | 2018-02-13 | 安进研发（慕尼黑）股份有限公司 | 由cd3特异性结合结构域导致的不良作用的预防 |
| ME03440B (me) | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| CN104487587A (zh) | 2012-04-20 | 2015-04-01 | 新兴产品开发西雅图有限公司 | Cd3结合多肽 |
| CN104822704B (zh) | 2012-06-14 | 2020-02-14 | 医疗生物科学有限公司 | 针对分化簇3(cd3)的人源化的抗体 |
| EP3786183A3 (en) | 2012-06-15 | 2021-06-09 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| RU2015117393A (ru) * | 2012-10-08 | 2016-12-10 | Роше Гликарт Аг | Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения |
| HRP20191865T1 (hr) | 2013-01-14 | 2020-01-10 | Xencor, Inc. | Novi heterodimerni proteini |
| EA201891502A1 (ru) * | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| WO2015172800A1 (en) | 2014-05-12 | 2015-11-19 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
| HK1217023A1 (zh) | 2013-05-28 | 2016-12-16 | Numab Innovation Ag | 新型抗体 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| BR112016009919A2 (pt) | 2013-11-04 | 2017-12-05 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| RU2016151235A (ru) | 2014-05-28 | 2018-06-28 | Ф. Хоффманн-Ля Рош Аг | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус |
| WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP2982693A1 (en) | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| EP3247725B1 (en) | 2015-01-23 | 2020-07-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| ES3012402T3 (en) | 2015-04-13 | 2025-04-09 | Pfizer | Therapeutic antibodies and their uses |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3345928B1 (en) | 2015-07-10 | 2020-06-24 | Merus N.V. | Human cd3 binding antibody |
| IL256562B2 (en) | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CN108290951B (zh) | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
| CN107849137B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗ceaxcd3 t细胞活化性抗原结合分子 |
| KR20180097615A (ko) * | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| CN109641046B (zh) | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | ANTIBODIES BINDING CD3 |
-
2017
- 2017-06-01 EP EP17173980.8A patent/EP3409322A1/en not_active Ceased
-
2018
- 2018-05-29 AU AU2018276345A patent/AU2018276345B2/en active Active
- 2018-05-29 MX MX2019014291A patent/MX2019014291A/es unknown
- 2018-05-29 WO PCT/EP2018/063996 patent/WO2018219901A1/en not_active Ceased
- 2018-05-29 JP JP2019566227A patent/JP2020521798A/ja active Pending
- 2018-05-29 CA CA3064668A patent/CA3064668A1/en active Pending
- 2018-05-29 KR KR1020197038296A patent/KR20200014345A/ko not_active Ceased
- 2018-05-29 EP EP18728846.9A patent/EP3630290A1/en active Pending
- 2018-05-29 CN CN201880034781.2A patent/CN110678228A/zh active Pending
- 2018-05-29 BR BR112019025062-0A patent/BR112019025062A2/pt unknown
- 2018-05-31 TW TW107118608A patent/TWI892958B/zh active
-
2019
- 2019-11-22 US US16/693,056 patent/US20200199230A1/en not_active Abandoned
- 2019-11-24 IL IL270867A patent/IL270867A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11633408B2 (en) | Prevention of adverse effects caused by CD3 specific binding domains | |
| JP2020099324A5 (enExample) | ||
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| FI3886875T3 (fi) | Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä | |
| JP2016520082A5 (enExample) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| JP2018508483A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| WO2019160751A3 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| JP2020527332A5 (enExample) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2019503387A5 (enExample) | ||
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2020521798A5 (enExample) | ||
| JP2021506817A5 (enExample) | ||
| JPWO2019246356A5 (enExample) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| CN112955148A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JPWO2020223702A5 (enExample) | ||
| JP2022513036A (ja) | がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ | |
| WO2023016826A3 (en) | Method and means for enhancing therapeutic antibodies | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| JPWO2021257124A5 (enExample) |